• Endo adds ADRENALIN^® premixed IV bags in concentrations of 2 mg, 5 mg, and 10 mg per 250 mL.
• Endo now offers ADRENALIN^® premixed IV bags in five of the most used concentrations, including the 5 mg and 10 mg which align with ASHP’s Standardize 4 Safety Initiative
• Endo’s products are the first FDA-approved, commercially available manufacturer-prepared epinephrine premixed intravenous (IV) bag.

Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today the launch of ADRENALIN^® (epinephrine in 0.9% sodium chloride injection) premixed IV bags in three new concentrations: 2 mg/250 mL, 5 mg/250 mL (20 mcg/mL), and 10 mg/250 mL (40 mcg/mL).

With this launch, Endo expands its ADRENALIN^® portfolio to include premixed IV bags in five concentrations: 2 mg, 4 mg, 5 mg, 8 mg, and 10 mg per 250 mL. The portfolio also includes ADRENALIN^® (epinephrine injection, USP) in 1 mL single-dose and 30 mL multi-dose vials. Read More >